Status:
ENROLLING_BY_INVITATION
Clinical Effectiveness-Implementation Hybrid Type 2 Study on Home-Delivered Cabenuva for People Living With HIV Who Are Not Retained in Care
Lead Sponsor:
Whitman-Walker Institute
Collaborating Sponsors:
ViiV Healthcare
Conditions:
HIV
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to assess adherence to home-delivered long-acting injectable rilpivirine/cabotegravir (Cabenuva) among people living with HIV enrolled in the Mobile Outreach Retention and...
Detailed Description
Advances in HIV treatment could promote better health and racial equity to address the gaps seen across the HIV care continuum nationally and locally. In Washington DC, HIV viral load suppression amon...
Eligibility Criteria
Inclusion
- HIV-infected individuals, aged 18 years or older, who are eligible to receive Cabenuva as standard of care at Whitman-Walker Health
- For those participants who will be prospectively enrolled via informed consent and offered survey and qualitative interviews, participants will be those receiving HIV-related treatment via the MORE program
Exclusion
- HIV-uninfected individuals
Key Trial Info
Start Date :
November 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 30 2025
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT06062979
Start Date
November 1 2023
End Date
June 30 2025
Last Update
April 25 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Whitman-Walker 1525 Clinic
Washington D.C., District of Columbia, United States, 20009
2
Whitman-Walker Max Robinson Center
Washington D.C., District of Columbia, United States, 20032